Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Alzheimer's & Dementia - Tập 8 - Trang 65-73 - 2012
Hugo Vanderstichele1, Mirko Bibl2, Sebastiaan Engelborghs3,4, Nathalie Le Bastard3, Piotr Lewczuk5, Jose Luis Molinuevo6, Lucilla Parnetti7, Armand Perret-Liaudet8,9, Leslie M. Shaw10, Charlotte Teunissen11, Dirk Wouters1, Kaj Blennow12
1Innogenetics NV (now part of Fujirebio), Ghent, Belgium
2Department of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Essen, Germany
3Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA), Middelheim and Hoge Beuken, Antwerp, Belgium
4Reference Centre for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
5Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Erlangen, Germany
6Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic i Universitari, Barcelona, Spain
7Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy
8Centre for Memory Resources and Research (CMRR), Neurobiology Laboratory, GHE, Hôpitaux de Lyon, Lyon, France
9Centre de Recherche en Neurosciences de Lyon (équipe BioRaN). Université Lyon 1 - CNRS UMR5292 - INSERM U1028, Lyon, France
10Department of Pathology and Laboratory Medicine, Perelman Medical Center, University of Pennsylvania, Philadelphia, PA, USA
11Neurology Laboratory Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
12Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Tóm tắt

AbstractBackground

Numerous studies show that the cerebrospinal fluid biomarkers total tau (T‐tau), tau phosphorylated at threonine 181 (P‐tau181P), and amyloid‐β (1‐42) (Aβ1–42) have high diagnostic accuracy for Alzheimer's disease. Variability in concentrations for Aβ1–42, T‐tau, and P‐tau181P drives the need for standardization.

Methods

Key issues were identified and discussed before the first meeting of the members of the Alzheimer's Biomarkers Standardization Initiative (ABSI). Subsequent ABSI consensus meetings focused on preanalytical issues.

Results

Consensus was reached on preanalytical issues such as the effects of fasting, different tube types, centrifugation, time and temperature before storage, storage temperature, repeated freeze/thaw cycles, and length of storage on concentrations of Aβ1–42, T‐tau, and P‐tau181P in cerebrospinal fluid.

Conclusions

The consensus reached on preanalytical issues and the recommendations put forward during the ABSI consensus meetings are presented in this paper.


Tài liệu tham khảo

10.1016/S0140-6736(05)67889-0 10.1002/gps.1652 10.1212/WNL.56.9.1143 Morris JC, 1999, Alzheimer's Disease, 11 Cummings JL, 2002, Definitions and diagnostic criteria S. Gauthier. Clinical Diagnosis and Management of Alzheimer's Disease, 3 10.1016/j.neurobiolaging.2007.02.016 10.1016/j.jalz.2011.03.005 10.1016/j.jalz.2011.03.008 10.1016/S1474-4422(10)70223-4 10.1016/j.jalz.2011.03.003 10.1016/j.jalz.2011.03.008 Fishman RA, 1992, Cerebrospinal fluid in diseases of the nervous system 10.1097/01.wad.0000194014.43575.fd 10.1159/000311703 10.1111/j.1600-0447.1993.tb03443.x 10.1002/1531-8249(200009)48:3<402::AID-ANA23>3.0.CO;2-G 10.1001/jama.289.16.2094 10.1002/emmm.200900048 10.1016/S0009-8981(03)00121-9 The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association of the National Institute on Aging Working Group, 1988, Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease, Neurobiol Aging, 19, 109 10.1016/S1474-4422(03)00530-1 10.1016/S0361-9230(03)00086-8 10.1212/01.WNL.0000123249.58898.E0 10.1016/j.neurobiolaging.2008.10.017 10.1212/WNL.0b013e31821ccc98 10.1212/01.WNL.0000140289.18472.15 10.1212/01.WNL.0000140290.80962.BF 10.1002/ana.21610 10.3233/JAD-2010-101422 10.1001/archneurol.2009.316 10.1159/000313534 10.1001/jama.1996.03530310034029 10.1111/j.1468-1331.2009.02753.x 10.3109/13506120009146438 10.1093/clinchem/47.10.1776 10.1212/WNL.0b013e3181c47cc2 10.1038/nrneurol.2010.4 10.1016/j.sleep.2007.11.002 10.1212/01.wnl.0000256043.50901.e3 10.1002/ana.21623 MBjerke EPortelius LMinthon AWallin HAnckarsäter RAnckarsäter et al.Confounding factors influencing amyloid beta concentration in cerebrospinal fluid.Int J Alzheimers Dis2010 pii: 986310 DSlats.Hour‐to‐hour variability CSF biomarkers in AD patients. Presented at the Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD) July 10–15 2010 Honolulu Hawaii. 10.2174/157488908784534595 Vanderstichele H, 2008, BioMarkers for Early Diagnosis of Alzheimer's Disease, 81 10.1001/archneur.56.6.673 10.1373/clinchem.2005.058776 APerret‐Liaudet MPelpel SLehmann SSchraen HVanderstichele IQuadrio et al.Sampling tube a critical factor in Alzheimer Disease Biomarker Standardization. Hot topics in International Conference on Alzheimer's Disease July 10–15 2010 Honolulu Hawaii. 10.1016/j.cca.2010.07.019 10.1385/NCC:4:2:153 10.1054/jocn.1999.0193 CETeunissen NAVerwey MIKester KvanUffelen MABlankenstein.Standardization of assay procedures for analysis of the CSF biomarkers amyloid β(1‐42) tau and phosphorylated tau in Alzheimer's disease: report of an International Workshop.Int J Alz Dis2010 Zimmerman R, 2011, Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnosis, J Alz Dis, 25, 739 10.1002/pmic.200402039 10.1373/clinchem.2004.039735 10.1515/CCLM.2007.160 10.1002/ana.1032 10.1002/elps.200305992 10.1002/prca.200700126 10.1002/prca.200700330
Thông tin
Thông tin xuất bản

Alzheimer's & Dementia

Tập 8

65-73

Thông tin tác giả